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Glioblastoma multiforme (GBM) is widely recognized as the most common and lethal of the 
malignant gliomas. Few effective therapeutic treatments are available as five-year survival 
rates of diagnosed individuals are less than five percent. Luteolin, a common flavonoid found 
in a variety of fruits and vegetables, has demonstrated significant promise in combating 
cancers of the breast, colon, liver, lung, and bone. In this study, we investigated the effects of 
luteolin on glioblastoma multiforme cell lines U-251, U-87, and U-1242. Cell viability was 
assessed using cell count with trypan blue exclusion and MTT assays. Results revealed that 
luteolin reduces GBM cell viability and cell proliferation in a time and concentration-
dependent manner. Western Blot analysis indicated that luteolin decreased AKT, ERK, and 
MAPK phosphorylation following treatment with EGF. Additionally, luteolin promoted 
apoptosis in GBM cells by inducing PARP and caspase-3 cleavage, and decreasing levels of 
the anti-apoptotic protein BCL-XL. Our results indicate that luteolin exhibits a biological 
effect and may be used as a therapeutic agent for glioblastoma multiforme. 
